Panobinostat (LBH589)

For research use only.

Catalog No.S1030 Synonyms: NVP-LBH589

227 publications

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 117 In stock
USD 70 In stock
USD 90 In stock
USD 270 In stock
USD 397 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Panobinostat (LBH589) has been cited by 227 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 NVXjSWZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLvVGoxNTFyIN88US=> NEnOcGoxNTRiZB?= NGXWSXVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnHrNlY4ODJ5OES=
HepG2 NWXC[41sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLhfZExNTFyIN88US=> M2HXUFAuPCCm MmPybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVWyOlcxOjd6NB?=
HT29 MXLGeY5kfGmxbjDBd5NigQ>? MkXEOVDDqG6P MY[yOE04OiCq MWrpcoR2[2WmIHHjeIl3[XSrb36gc4Yh[2G|cHHz[UA{KGGodHXyJFQ5yqCqwrC= M2XxfFI3PzB{N{i0
HepG2 NVSwTXoyTnWwY4Tpc44hSXO|YYm= NGHNb3Y2OMLibl2= M37YfVI1NTd{IHi= M{HU[olv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhOjUEoHlCpC=> NEP6XGgzPjdyMke4OC=>
HCC827 MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DLUFUwPy53L{GwJI5O MWC3NuKhcA>? NFTVUXFFVVOR Mljv[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? MV6yOlY4PTR6NB?=
A549  MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHCNVAwOTVxMkCgcm0> MofuO|LDqGh? MkD1SG1UVw>? NGLx[HBmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?= MoLPNlY3PzV2OES=
NCI-H460  NYK1NohwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEO3NVMyOC9{MD:zNEBvVQ>? NHL3W|Y4OsLiaB?= NEjjeGlFVVOR Mort[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? NV\6N4Y5OjZ4N{W0PFQ>
J89GFP NXLDe3FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[2fGROW00EoB?= MlHTSWM2OD12OT64OUDDuSBzMj62OUBvVQ>? NWj3c2pHOjZ3NkO1Olg>
THP89GFP NGraNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3CSG1UV8Li NWT6fnp1TUN3ME2xPU4{PCEEsTC2MlQ{KG6P MYSyOlU3OzV4OB?=
SK-NEP-1 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCwMlAy6oDVMUCuNEDPxE1? MWWyOEBp M3nMXGROW00EoB?= NIjEUYdKSzVyPUe2MlM1KG6P MoXmNlYyPzZ{MUm=
G401 M32wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVSwMlAy6oDVMUCuNEDPxE1? M{fNUVI1KGh? NWjYSYZqTE2VT9Mg MljwTWM2OD1zNEOuNFIhdk1? NX\sb5hHOjZzN{[yNVk>
SK-NEP-1 NIX5c4ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGT1UYo2OCCwTR?= NULwPIpJOeLCk{Sg[C=> M3nFc2ROW00EoB?= M{TYOpJm\HWlZYOgZ4VtdCC|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? NVnXPGVKOjZzN{[yNVk>
G401 NYfZNFZOS2WubDDWbYFjcWyrdImgRZN{[Xl? MV[1NEBvVQ>? NYe1dnNzOeLCk{Sg[C=> MXzEUXNQyqB? M3u4bZJm\HWlZYOgZ4VtdCC|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? MlzoNlYyPzZ{MUm=
SK-NEP-1 NIPVSmNCeG:ydH;zbZMhSXO|YYm= NInjTpg2OC9zMECgcm0> M33PZlI1KGh? NEjib4dFVVORwrC= NV70SHJNcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NF\QfYwzPjF5NkKxPS=>
G401 NXHtTlJmSXCxcITvd4l{KEG|c3H5 MX[1NE8yODBibl2= MlvGNlQhcA>? NG\OZZpFVVORwrC= M3vUSolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYqyOlE4PjJzOR?=
SK-NEP-1 MlX4SpVv[3Srb36gRZN{[Xl? NFjRRWQ2OC9zMECgcm0> NW\QNo17OjRiaB?= NW[4T2s{TE2VT9Mg MnX0d4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>? MknENlYyPzZ{MUm=
G401 MmnYSpVv[3Srb36gRZN{[Xl? NHX2UJU2OC9zMECgcm0> MV:yOEBp MVTEUXNQyqB? NVz5ZmdGe2ixd4OgeIhmKGmwZIXjeIlwdiCxZjDEUmEh\nKjZ33lcpRifGmxbh?= M13HXlI3OTd4MkG5
SK-NEP-1 NHzUT2hHfW6ldHnvckBCe3OjeR?= M332dlUxNzFyMDDuUS=> M1HvXVI1KGh? M3LSWGROW00EoB?= NW\DSIxFcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? NYf0NYJrOjZzN{[yNVk>
G401 M1rkNGZ2dmO2aX;uJGF{e2G7 NI\NcYI2OC9zMECgcm0> NHize|AzPCCq MYrEUXNQyqB? NXTnfZVqcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? M3K5SFI3OTd4MkG5
RPMI 8226 M{m0WWNmdGxiU4Xyeol3[WxiQYPzZZk> NVvLS4tYOi92L{[gcm0> NVOxTlVFPDkkgJno NFH4NmtqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq NUPzSZNCOjZyMECyPVI>
OPM2 MlrER4VtdCCVdYL2bZZidCCDc4PhfS=> NVfWN3E{Oi92L{[gcm0> NIrtTmQ1QOLCiXi= MXfpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp M4fIRlI3ODByMkmy
U266 M{HINWNmdGxiU4Xyeol3[WxiQYPzZZk> MnTLNk81NzZibl2= NILaTII1QOLCiXi= M4r0bIlv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? MWCyOlAxODJ7Mh?=
H929 NIHjeGVE\WyuIGP1dpZqfmGuIFHzd4F6 M3rvfVIwPC94IH7N NWniUo04PDkkgJno NVnvR2FscW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= MlH0NlYxODB{OUK=
RPMI 8226  NFjm[olCeG:ydH;zbZMhSXO|YYm= MUe05qCKdk1? NV\p[Gt[OjRxNEigbC=> NXG1WWZWcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NVvuSplSOjZyMECyPVI>
HCC827 NVTBcFk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGOxPZkyOCCwTR?= Mn7aOFghcA>? NHeycXRFVVOR MUTlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>? NIHtS5YzPTl2NE[xOy=>
NCI-H23 MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPyb3YyOCCwTR?= MnXiOFghcA>? MVvEUXNQ NXPRdG5H\W6qYX7j[ZMh[2m|cHzheIlvKHOnboPpeIl3cXS7wrC= MX2yOVk1PDZzNx?=
AML3 M3X6UGZ2dmO2aX;uJGF{e2G7 MknLNE0yKM7:TR?= MnLTNlTDqGh? M3TxdYlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3;HPFI2PjF{OUSx
ML-1 MljXSpVv[3Srb36gRZN{[Xl? MnTaNE0yKM7:TR?= MWOyOOKhcA>? MonjbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NXn3SI9rOjV4MUK5OFE>
RPMI-8226vr10  MnTDSpVv[3Srb36gRZN{[Xl? Ml7yNE0yKM7:TR?= M1LVeVI1yqCq MWHpcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHzEWZkzPTZzMkm0NS=>
ML-1 NEHpPYdHfW6ldHnvckBCe3OjeR?= NWPBendXOSEQvF2= MUWyOOKhcA>? NVjkcI1ZcW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB2LX\vcIQ> NGrWd2YzPTZzMkm0NS=>
RPMI-8226vr10  NUjtVZN4TnWwY4Tpc44hSXO|YYm= MWWxJO69VQ>? MlPFNlTDqGh? NGDKVIhqdmO{ZXHz[ZMh[2G|cHHz[U0{KGGldHn2bZR6KDJwNT3mc4xl NVnjRZRGOjV4MUK5OFE>
SK-N-BE (2) MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjPXZUzPOLCiXi= MlXHTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P NFjsOmMzPTNyOEmxOi=>
SK-N-BE (2), PAN  MK NFTyd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rGdFI16oDLaB?= M4\3UmlEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?= MknVNlU{ODh7MU[=
SK-N-BE (2), MK  PAN MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7sWHBFOjUkgJno MUfJR|UxRTN6Mj6w5qCKyrIkgJm0N{4zKG6P NUntOmsxOjV|MEi5NVY>
SK-N-AS NH21XXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrlOWszPOLCiXi= M3vJdGlEPTB;M{euNgKBkcLz4pEJNk41KG6P MWiyOVMxQDlzNh?=
SK-N-DZ NX;4[GRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVSyOQKBkWh? NIiyVoVKSzVyPUG3MlHjiIoEsfMAjVAvPCCwTR?= M3TvbVI2OzB6OUG2
Caki-1 M3;BWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr5OVEyOC9{NT:1NEBvVQ>? Ml\qOFghcA>? MYDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? M{[xSVI2Ojd7MUmx
ACHN NInYT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzhNVAwOjVxNUCgcm0> MXW0PEBp M4Dhe4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= NHfkbJMzPTJ5OUG5NS=>
769-P NV;SW3RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLQNVAwOjVxNUCgcm0> NX61bpB{PDhiaB?= MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? MV[yOVI4QTF7MR?=
786-O  MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfLfI84OTBxMkWvOVAhdk1? MnLBOFghcA>? NI[ybXNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= NEfH[GgzPTJ5OUG5NS=>
Caki-1 MoLCRZBweHSxc3nzJGF{e2G7 M{TvR|UxKG6P MleyOFghcA>? NU\iVodncW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= MVeyOVI4QTF7MR?=
ACHN NYnYVlg5SXCxcITvd4l{KEG|c3H5 NGLCOXE2OCCwTR?= NGD3O4E1QCCq NH3FOHVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= NEDNNpUzPTJ5OUG5NS=>
769-P MlnnRZBweHSxc3nzJGF{e2G7 NFPoSIs2OCCwTR?= NYTaPGdLPDhiaB?= NF74fJVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= M{fTVVI2Ojd7MUmx
786-O  MnHvRZBweHSxc3nzJGF{e2G7 M2TFS|UxKG6P NUfKNHVZPDhiaB?= MlnhbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? NYXJc5FROjV{N{mxPVE>
Caki-1 NUH6eohCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYiyOU82OCCwTR?= NX70[3lqPDhiaB?= NHfiTI5FVVOR MYrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk NF[yfGUzPTF5NkO1OC=>
ACHN MkHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPydodEOjVxNUCgcm0> M3vxUlQ5KGh? MkniSG1UVw>? NWD4VJVwcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> MVqyOVE4PjN3NB?=
769-P NUT5dWFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX6xc|FnOjVxNUCgcm0> M4HidlQ5KGh? NXPlcpY5TE2VTx?= MV7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk MXWyOVE4PjN3NB?=
Caki-1 NHHmToVEd2yxbomgSo9zdWG2aX;uJGF{e2G7 NGrXdYY2OCCwTR?= MXK3MVE1KGR? NXXDNWJiTE2VTx?= M{PNcpN2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh MnXBNlUyPzZ|NUS=
ACHN NEXDOWhEd2yxbomgSo9zdWG2aX;uJGF{e2G7 MYi1NEBvVQ>? NG\kUZA4NTF2IHS= NWDKXnI6TE2VTx?= NYnxW5BZe3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB? MViyOVE4PjN3NB?=
769-P MVzDc4xwdnliRn;ycYF1cW:wIFHzd4F6 NHWxcJo2OCCwTR?= NHH4WZY4NTF2IHS= NXe1cm5QTE2VTx?= M{jRPZN2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh NEDUcVAzPTF5NkO1OC=>
Caki-1 NIDrTJdCeG:ydH;zbZMhSXO|YYm= NWfHO|lSPTBibl2= NGLjeIY1QCCq NXTWXnJuTE2VTx?= NH\tfVlqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MkOxNlUyPzZ|NUS=
ACHN NVjLbGZZSXCxcITvd4l{KEG|c3H5 NFnhTXE2OCCwTR?= MmH2OFghcA>? MYrEUXNQ NH\0Oo9qdmS3Y3XzJINmdGxiYYDvdJRwe2m| MoTTNlUyPzZ|NUS=
769-P NUXVR5BDSXCxcITvd4l{KEG|c3H5 M3LJNVUxKG6P MlvmOFghcA>? M3zKcGROW09? NF25fohqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MUeyOVE4PjN3NB?=
MDA-MB-231 MV;Nc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> Mof3NVDDqG6P NHGxd3g{yqCm NHWxe3JFVVOR MVHhcJRmenNiY3XscEBud3KyaH;sc4d6yqB? MX2yOFgyODR7Nx?=
BT-549 MontUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 NXXiUlBWOTEEoH7N NWHHSYt5O8LiZB?= MmnvSG1UVw>? MlrwZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi NX;y[HNLOjR6MUC0PVc>
MCF-7  M4PhVW1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? Mli4NVDDqG6P Ml3rN:Kh\A>? MnG1SG1UVw>? NUH2fVdZ[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg MYOyOFgyODR7Nx?=
MCF-7 M1rpfWZ2dmO2aX;uJGF{e2G7 M2TnNlUuPTBibl2= M3qzfFI1KGh? NIDmWGNFVVOR MXny[YR2[2WmIITo[UBt\X[nbDDv[kBmgHC{ZYPzbY9vKG:oIFXS{tEtKFCUIHHu[EBHd3iDMdMg M2TOXFI1OzZ4NEC3
CTS Ml7RRZBweHSxc3nzJGF{e2G7 Mon4NQKBmzRyIH7NxsA> NIDTenU1QCCq MonXbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MkjUNlQzPDR2Mkm=
OCI-AML3  MYLBdI9xfG:|aYOgRZN{[Xl? MYGw5qCUPDBibl5CpC=> M{LsPFQ5KGh? NWfNd3ZycW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mlj4NlQzPDR2Mkm=
U937 MV7BdI9xfG:|aYOgRZN{[Xl? M163SlDjiJN2MDDuUeKh M1XHNVQ5KGh? NIDKdGpqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NXW0cJVtOjR{NES0Nlk>
PC3 MlLtRZBweHSxc3nzJGF{e2G7 NETjToUxNTFyMDDuUS=> M4DENlI1NzR6IHi= NVLxOmJQcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYGyOFE3OzJ|MB?=
PC3-AR NInFSZBCeG:ydH;zbZMhSXO|YYm= M2TLW|AuOTByIH7N M4XDflI1NzR6IHi= M{XPOYlv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWP2c4NEOjRzNkOyN|A>
PC3 NUTtb5JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TSfFAuOTByIH7N MUGyOE81QCCq M3vFUolv\HWlZYOgZYNkfW23bHH0bY9vKG:oIIP1ZmcyKHCxcIXsZZRqd25? NVy4S25[OjRzNkOyN|A>
PC3-AR NYK1b2FzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MViwMVExOCCwTR?= MmLLNlQwPDhiaB?= NHnx[IRqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKHSqZTDHNm0heGijc3W= NUjuXYFJOjRzNkOyN|A>
PC3 NEn2[2VHfW6ldHnvckBCe3OjeR?= MXiwMVExOCCwTR?= NY\hd4pCOjRiaB?= Ml6xd5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6= MV[yOFE3OzJ|MB?=
PC3-AR NHroW45HfW6ldHnvckBCe3OjeR?= Mn\0NE0yODBibl2= NIPBbVYzPCCq M375c5N2eHC{ZYPz[ZMh\XiycnXzd4lwdiCxZjDhZ5RqfmG2ZXSgRXRONCCDa4SgZY5lKEW{a{GvNkBxem:2ZXnu NHPkeJAzPDF4M{KzNC=>
OS-RC-2 NGT3OGpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVHlS4UxOC1zMECwJI5O NFj0TXgzPC92OD:3NkBp M{flNmROW09? NHfDd3Bl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz M1HKe|I1OTR2N{O3
OS-RC-2 M{fCS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWe1NEBvVQ>? Mnr4OFghcA>? MW\EUXNQ MkHRbY5lfWOnczDHNk9OKGG{cnXzeC=> NY\4b|hbOjRzNES3N|c>
OS-RC-2 NI[5SWNCeG:ydH;zbZMhSXO|YYm= M332VlUxKG6P NFX4R|U1QCCq M1XxdmROW09? MVTpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M2j1NFI1OTR2N{O3
SK-N-AS M2C1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j6cVDjiJN6MDDuUS=> NWrBdIZ4PDhiaB?= MV3JR|UxRTJ5LkSgcm0> MkfjNlQxQTh5OUm=
SK-N-DZ NWHsXJExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NImzS4Ux6oDVOECgcm0> MXW0PEBp MlPQTWM2OD1{MT65JI5O NVPRfopTOjRyOUi3PVk>
SK-N-SH NXz6TGdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTEbFhbOOLCk{iwJI5O MkS2OFghcA>? MX\JR|UxRTd{LkOgcm0> M1r0R|I1ODl6N{m5
SK-N-BE MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLiVVJ[OOLCk{iwJI5O NGHi[nk1QCCq NIT3eIxKSzVyPUe1MlQhdk1? MWOyOFA6QDd7OR?=
SK-N-AS MoXERZBweHSxc3nzJGF{e2G7 MXyw5qCUQDBibl2= NFP3[ZI1QCCq Mki4dI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u NVLjSHZWOjRyOUi3PVk>
SK-N-DZ MkXFRZBweHSxc3nzJGF{e2G7 NIfZUHox6oDVOECgcm0> MlXaOFghcA>? NYnvSWN4eG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v NVHLeWJsOjRyOUi3PVk>
SK-N-SH NVWzW4lMSXCxcITvd4l{KEG|c3H5 NF3PfoUx6oDVNECgcm0> NHLYOFE1QCCq M4T1dpBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> Ml73NlQxQTh5OUm=
SK-N-BE M2jzSGFxd3C2b4Ppd{BCe3OjeR?= NHv6PI0x6oDVNECgcm0> MX:0PEBp M4jqb5BwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> NEnLfZEzPDB7OEe5PS=>
SK-N-AS M2PGdWZ2dmO2aX;uJGF{e2G7 NYDl[5F1OOLCk{iwJI5O MlHROFghcA>? NWS2S3p1cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? NVPwdlFFOjRyOUi3PVk>
SK-N-DZ Mo\FSpVv[3Srb36gRZN{[Xl? NFPSUZIx6oDVOECgcm0> NEjSVYw1QCCq NFLFSHVqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR MYSyOFA6QDd7OR?=
SK-N-SH MVfGeY5kfGmxbjDBd5NigQ>? NEjPfIIx6oDVNECgcm0> NGnFNWs1QCCq NEnlXXdqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR MViyOFA6QDd7OR?=
SK-N-BE NIrRUG5HfW6ldHnvckBCe3OjeR?= NWPqPIhZOOLCk{SwJI5O NYHEPZRjPDhiaB?= MnvsbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> MXKyOFA6QDd7OR?=
HCC-LM3 NHuybpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWGxMVExODBibl2= MnnvNlQwPDhxN{KgbC=> MY\EUXNQ MWnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MW[yOFA6Ozl3Nh?=
HepG2 M1;OR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCxMVExODBibl2= NGjzOG0zPC92OD:3NkBp NX;De5FFTE2VTx?= NET1RZlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MlnRNlQxQTN7NU[=
SMMC-7721 NH3lS|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7WNU0yODByIH7N M2npfFI1NzR6L{eyJIg> M3;lemROW09? MmDsbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NEjhSI8zPDB7M{m1Oi=>
HCC-LM3 MXLBdI9xfG:|aYOgRZN{[Xl? NULXVY9OPTBibl2= MX20PEBp MVrEUXNQ MlvabY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> NFHoSnYzPDB7M{m1Oi=>
HepG2 NYLKfoZDSXCxcITvd4l{KEG|c3H5 MmL5OVAhdk1? M36xRVQ5KGh? Ml;OSG1UVw>? NF:5PYZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? MYmyOFA6Ozl3Nh?=
SMMC-7721 MVTBdI9xfG:|aYOgRZN{[Xl? M2\SeFUxKG6P MorlOFghcA>? MUDEUXNQ NX7rU21wcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? MVmyOFA6Ozl3Nh?=
HCC-LM3 M2jNPGZ2dmO2aX;uJGF{e2G7 NVi2SllLPTBxMUCwJI5O MoDiNlQhcA>? NV\mcWw2TE2VTx?= M1XXSoRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= NFzIR2wzPDB7M{m1Oi=>
HepG2 NI\LRWxHfW6ldHnvckBCe3OjeR?= M{fFbVUxNzFyMDDuUS=> NYX4eItKOjRiaB?= MknwSG1UVw>? NX\KPVR[\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> NXH4dIhLOjRyOUO5OVY>
SMMC-7721 NVvGUXBRTnWwY4Tpc44hSXO|YYm= NEf5OXU2OC9zMECgcm0> MVKyOEBp NXu3eJpMTE2VTx?= NYjRdZI1\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> M3;hU|I1ODl|OUW2
HCC-LM3 M3Hjd2Z2dmO2aX;uJGF{e2G7 NHfFcXg2OC9zMECgcm0> M1\0[lI1KGh? NICwcnVFVVOR MUPkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v NFv0ZZUzPDB7M{m1Oi=>
HepG2 M17ISGZ2dmO2aX;uJGF{e2G7 NFXjcHA2OC9zMECgcm0> NYnKV5QyOjRiaB?= NEPIZWlFVVOR M1XEe4Rwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25? NFXPSXMzPDB7M{m1Oi=>
SMMC-7721 NEK0S29HfW6ldHnvckBCe3OjeR?= NVrKXmdzPTBxMUCwJI5O MorwNlQhcA>? MXzEUXNQ M2TGcYRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25? Mk\JNlQxQTN7NU[=
FaDu MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHWbpJOOTBy4pEFcm0> M3ywbVgwOTBxMUKgbC=> NWfNbnln\Gm|cHzhfYVlKGFic3nncolncWOjboSgZY5lKHC{b3zvcodm\CCJMj;NJIFzemW|dDDheEA5KGGwZDCxNwKBjWhicH;zeEBz\WynYYPl NHv3R5EzPDB{NkS4Ni=>
FaDu MV7GeY5kfGmxbjDBd5NigQ>? NVXScIpVOTBy4pEFcm0> Ml\UNk81NzhxMUKgbC=> NGPTW2pqdmS3Y3XkJJAzOVejZkGvR4lxOcLiZYjwdoV{e2mxbh?= NIDaOmczPDB{NkS4Ni=>
PC-3  NX3qdFVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXYNE0yOCEQvF2= MVKyOE81QC95MjDo NXv6ZpJlcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M2LCUVI{QTlzMkG2
LNCaP M2TPZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqwMVUh|ryP M4jNUVI1NzR6L{eyJIg> MXHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnW5NlM6QTF{MU[=
RWPE-1  MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmwMVIxKM7:TR?= MnHiNlQwPDhxN{KgbC=> M1\kVYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYr5UGhYOjN7OUGyNVY>
Capan-1 MoTPSpVv[3Srb36gRZN{[Xl? NWW5blJnOjVxNUCvNVAxKG6P NU\je4Q3QC9{ND:0PEBp MXTEUXNQ NGPWfZVld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n M3i2ZVI{QTJ{OEi2
L3.6pl NXjSdZJMTnWwY4Tpc44hSXO|YYm= M2jZ[FI2NzVyL{GwNEBvVQ>? M{LNU|gwOjRxNEigbC=> M4jJRWROW09? Mkmw[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= Mn7jNlM6OjJ6OE[=
CFPAC-1  M3;zcGZ2dmO2aX;uJGF{e2G7 NEjTO3UzPS93MD:xNFAhdk1? NHLHN5o5NzJ2L{S4JIg> MXPEUXNQ MUTkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p NWfoXIFKOjN7MkK4PFY>
Capan-1 NEf2NJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrIWmh3OjVxNUCvNVAxKG6P NXfXfnpIPDhiaB?= M1LI[GROW09? MWny[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4nVV|I{QTJ{OEi2
L3.6pl MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MornNlUwPTBxMUCwJI5O NVTLVmJVPDhiaB?= NYLnUopWTE2VTx?= MmjGdoVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NELGOWYzOzl{Mki4Oi=>
CFPAC-1  MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{noUlI2NzVyL{GwNEBvVQ>? Ml;WOFghcA>? MkDwSG1UVw>? M3rJXJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFzpTGgzOzl{Mki4Oi=>
Capan-1 MYPBdI9xfG:|aYOgRZN{[Xl? Mn64NlUwPTBxMUCwJI5O M{DaO|Q5KGh? MVLEUXNQ NEnldnJqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmPsNlM6OjJ6OE[=
L3.6pl M{\4XmFxd3C2b4Ppd{BCe3OjeR?= NH3rbWwzPS93MD:xNFAhdk1? M{TBflQ5KGh? MkDOSG1UVw>? NHv4XGhqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MoKyNlM6OjJ6OE[=
CFPAC-1  NIi3PJpCeG:ydH;zbZMhSXO|YYm= M4S5UlI2NzVyL{GwNEBvVQ>? M3LiOVQ5KGh? M1PBeGROW09? M3\XXolv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWTRPYZtOjN7MkK4PFY>
HN22 NYfUe2c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDDNE0zOCCwTR?= NInoe2EzPC92ODDo M4HhS2ROW09? M{fWZolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> MkHoNlM5Pzd{M{W=
HSC4  M4W0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LSNVAuOjBibl2= M{jDV|I1NzR6IHi= NI\wW|lFVVOR NV;Je4hXcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? NFvuZY0zOzh5N{KzOS=>
HN22 NHvtcoxCeG:ydH;zbZMhSXO|YYm= NF;1fngxNTJyIH7N NIjiXYo1QCCq M3f1TmROW09? NWO4[2NOcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NXm4bIJXOjN6N{eyN|U>
HSC4  NXK2RoJ3SXCxcITvd4l{KEG|c3H5 NW[wWVFnOC1{MDDuUS=> NUL4RWtRPDhiaB?= NXrRbpl3TE2VTx?= NGX0RoJqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NF7HU2IzOzh5N{KzOS=>
HN22 MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj6fHRuOC1{MDDuUS=> MYq0PEBp NILF[lZFVVOR MYXpcoR2[2W|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC= NYDUWVJ4OjN6N{eyN|U>
HSC4  NWLPfmw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXN[G4xNTJyIH7N NUT1bVU6PDhiaB?= MYfEUXNQ MWXpcoR2[2W|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC= MUmyN|g4PzJ|NR?=
HN22 M3Pvb2Z2dmO2aX;uJGF{e2G7 NHrW[JcxNTJyIH7N Mnv2OFghcA>? NGDXZ|dFVVOR M1PYUZN2eHC{ZYPz[ZMhW3BzIHX4dJJme3Orb39CpC=> NY[3TlJpOjN6N{eyN|U>
HSC4  NXzwcVhNTnWwY4Tpc44hSXO|YYm= NYjzfGNtOC1{MDDuUS=> NU[2dY5{PDhiaB?= MmjuSG1UVw>? NHjifZR{fXCycnXzd4V{KFOyMTDlfJBz\XO|aX;uxsA> MorKNlM5Pzd{M{W=
Cal62 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLrOYpTUUN3ME2zN{DDuSB2IH7N NGXxSmkzOzh{NEC2OC=>
Hth7 NVzzXZpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7ETWM2OD1zNTFCtUAzKG6P MkLTNlM5OjRyNkS=
Hth83 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzCTWM2OD1|NDFCtUA2KG6P MmjoNlM5OjRyNkS=
C643 NHy4VIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDnWIlKSzVyPUexJOKyKDFyIH7N NYizS3FyOjN6MkSwOlQ>
SW1736 MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjN[ldKSzVyPUO1JOKyKDhibl2= MWqyN|gzPDB4NB?=
T241 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjZU4FKSzVyPU[1JOKyKDdibl2= NU\uNFFwOjN6MkSwOlQ>
T351 NVz3U2ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHuTWM2OD13MDFCtUAyOCCwTR?= MXyyN|gzPDB4NB?=
BHP2-7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPEWGxKSzVyPUO3JOKyKDZibl2= MVuyN|gzPDB4NB?=
T238 NXPFZWY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEGzN2NKSzVyPUGsOVAxKMLzIEKwNEBvVQ>? NYPJcmJoOjN6MkSwOlQ>
HCT8 NHyx[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYK3NkBp NXzwRYY4TE2VTx?= MYPJR|UxRTF{LkpihKnDueLCiUGuPUBvVQ>? M2jx[FI{Ojl7M{i4
H630 NFzrboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33tb|czKGh? M1PjUWROW09? Mmm2TWM2OD1zMj605qCKyrIkgJmzMlEhdk1? Mlj2NlMzQTl|OEi=
cH630 5-FU-res NVe0eFJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUG3NkBp NX3SUYJLTE2VTx?= NVvN[|lVUUN3ME2xOU426oDLwsJihKkyNjJibl2= MmTsNlMzQTl|OEi=
HCT116 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDkO|IhcA>? NF\nVoxFVVOR M3jCbWlEPTB;MUCuO-KBkcLz4pEJNk4zKG6P MYKyN|I6QTN6OB?=
HCT116 p53−/− M4iwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvHcXJ5PzJiaB?= NIfaWVlFVVOR NIKydYNKSzVyPUiuOwKBkcLz4pEJNU44KG6P NE\NOo8zOzJ7OUO4PC=>
dHCT116 p21−/− M176PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITWN5Q4OiCq NIrzb|dFVVOR MVHJR|UxRTVwOfMAjeKy6oDLMT6zJI5O M4LyOlI{Ojl7M{i4
HT29 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XkXVczKGh? M1zEZ2ROW09? NVjnV|dlUUN3ME2xOk4{6oDLwsJihKkzNjNibl2= NF\ZU4ozOzJ7OUO4PC=>
LoVo MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHv[Gx3PzJiaB?= M4SwS2ROW09? NHPLVm9KSzVyPUWuNgKBkcLz4pEJNE43KG6P NU\BToR6OjN{OUmzPFg>
RKO NFHLdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rweFczKGh? NHHwNmlFVVOR NGX5XJdKSzVyPUeuPgKBkcLz4pEJNk4zKG6P NILGOnMzOzJ7OUO4PC=>
SW480 NGj3RXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPESpp6PzJiaB?= M3TB[GROW09? MWXJR|UxRTF5LkZihKnDueLCiUCuPEBvVQ>? MoP1NlMzQTl|OEi=
eSW620 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1faO|czKGh? MUXEUXNQ NHf3U2lKSzVyPUmuNgKBkcLz4pEJNk4yKG6P NEHmO3kzOzJ7OUO4PC=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 / EZH2; 

PubMed: 19279403     


Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control.

caspase-8 / cleaved caspase-8 / Sp1; 

PubMed: 27738323     


The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. 

c-Myc / IRF4; 

PubMed: 27738323     


RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting.

Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; 

PubMed: 28915627     


Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1.

RAD51 / BRCA1 / CHK1 / RPL13a; 

PubMed: 24244429     


CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells.

H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; 

PubMed: 31071955     


Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.

19279403 27738323 28915627 24244429 31071955
Immunofluorescence
Synaptophysin / NACM; 

PubMed: 28915627     


Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm.

α-tubulin / Acetyl-α-tubulin; 

PubMed: 29983882     


CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm.

BiP; 

PubMed: 23544167     


Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

ATF4; 

PubMed: 23544167     


HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

IRE1α / S724-IRE1α; 

PubMed: 23544167     


Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

28915627 29983882 23544167
Growth inhibition assay
Cell viability; 

PubMed: 27738323     


The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.

27738323
In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589
Smiles CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=C([NH]1)C=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04341311 Not yet recruiting Drug: Marizomib|Drug: Panobinostat Diffuse Intrinsic Pontine Glioma|Pediatric Brainstem Glioma|Pediatric Brainstem Gliosarcoma Recurrent|Pediatric Cancer|Pediatric Brain Tumor|Diffuse Glioma Dana-Farber Cancer Institute|Celgene|Secura Bio May 2020 Phase 1
NCT03632317 Withdrawn Drug: Panobinostat|Drug: Everolimus Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center October 2019 Phase 2
NCT03982134 Withdrawn Drug: PDR001|Drug: Panobinostat Melanoma|Non Small Cell Lung Cancer Muhammad Furqan|Novartis Pharmaceuticals|University of Iowa September 2019 Phase 1
NCT04326764 Recruiting Drug: Panobinostat Acute Myeloid Leukaemia (AML)|Myelodysplastic Syndromes (MDS) Goethe University|Jan J. Cornelissen (HOVON-SAKK)|Sebastian Giebel (PALG) July 24 2018 Phase 3
NCT03515915 Unknown status -- Patients With Recurrent or Refractory Multiple Myeloma University Hospital Montpellier|Poitiers University Hospital April 23 2018 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Panobinostat|Panobinostat ic50|Panobinostat price|Panobinostat cost|Panobinostat solubility dmso|Panobinostat purchase|Panobinostat manufacturer|Panobinostat research buy|Panobinostat order|Panobinostat mouse|Panobinostat chemical structure|Panobinostat mw|Panobinostat molecular weight|Panobinostat datasheet|Panobinostat supplier|Panobinostat in vitro|Panobinostat cell line|Panobinostat concentration|Panobinostat nmr|Panobinostat in vivo|Panobinostat clinical trial|Panobinostat inhibitor|Panobinostat Epigenetics inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID